Advances in understanding and treatment of scleromyxedema

References

• Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013;69:66.
   PubMed Web of Science ®Google Scholar
• Ferreli C, Gasparini G, Parodi A, et al. Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol. 2017 Jul 16. Epub ahead of print. DOI:10.1007/s12016-017-8625-4
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Merlo G, Carli C, et al. Histopathologic characteristics of scleromyxedema: a study of a series of 34 cases. J Am Acad Dermatol. 2016;74:1194–1200.
   PubMed Web of Science ®Google Scholar
• Le Moigne M, Mazereeuw-Hautier J, Bonnetblanc JM, et al. Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study. Ann Dermatol Venereol. 2010;137:782–788.
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44:273–281.
   PubMed Web of Science ®Google Scholar
• Boffa MJ, Ead RD. Spontaneous improvement of scleromyxoedema. Clin Exp Dermatol. 1995;20:157–160.
   PubMed Web of Science ®Google Scholar
• Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87:10–20.
   PubMed Web of Science ®Google Scholar
• Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33:37–43.
   PubMed Web of Science ®Google Scholar
• Godby A, Bergstresser PR, Chaker B, et al. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 1998;38:289–294.
   PubMed Web of Science ®Google Scholar
• Lee YH, Sahu J, O’Brien MS, et al. Scleroderma renal crisis-like acute renal failure associated with mucopolysaccharide accumulation in renal vessels in a patient with scleromyxedema. J Clin Rheumatol. 2011;17:318–322.
   PubMed Web of Science ®Google Scholar
• De Simone C, Castriota M, Carbone A, et al. Cardiomyopathy in scleromyxedema: report of a fatal case. Eur J Dermatol. 2010;20:852–853.
   PubMed Web of Science ®Google Scholar
• Sala AC, Cunha PR, Pinto CA, et al. Scleromyxedema: clinical diagnosis and autopsy findings. An Bras Dermatol. 2016;91:48–50.
   PubMed Web of Science ®Google Scholar
• Knobler R, Moinzadeh P, Hunzelmann N, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 2: scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol. 2017 Aug 8. DOI:10.1111/jdv.14466. [Epub ahead of print].
   Web of Science ®Google Scholar
• Nashel J, Steen V. Scleroderma mimics. Curr Rheumatol Rep. 2012;14:39.
   PubMed Web of Science ®Google Scholar
• Guarneri A, Cioni M, Rongioletti F. High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol. 2017;31:1157–1160.
   PubMed Web of Science ®Google Scholar
• Webster GF, Matsuoka LY, Burchmore D. The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol. 1993;28:105–108.
   PubMed Web of Science ®Google Scholar
• River Y, Levy I, Gilead L, et al. Fever, convulsions and coma in scleromyxedema: a ′′dermato-neuro syndrome′′. Neurology. 1996;46:1778–1779.
   PubMed Web of Science ®Google Scholar
• Fleming KE, Virmani D, Sutton E, et al. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature. J Cutan Pathol. 2012;39:508–517.
   PubMed Web of Science ®Google Scholar
• Charles S, Hainaut E, Cante V, et al. Dermato-neuro syndrome during scleromyxedema: efficacy of plasmapheresis and intravenous immunoglobulin. Ann Dermatol Venereol. 2014;141:523–527.
   PubMedGoogle Scholar
• Alligood TR, Burnett JW, Raines BL Jr. Scleromyxedema associated with esophageal aperistalsis and dermal eosinophilia. Cutis. 1981;28:60–63.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Aguirre KI, Stewart MW, Sluzevich JC. Scleromyxedema with retinal vasculitis and macular edema. Retin Cases Brief Rep. 2017;11:319–322.
   PubMedGoogle Scholar
• Chan JC, Trendell-Smith NJ, Yeung CK. Scleromyxedema: a cutaneous paraneoplastic syndrome associated with thymic carcinoma. J Clin Oncol. 2012;30:e27–9.
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol. 2001;23:257–267.
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Cozzani E, Parodi A. Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare. J Cutan Pathol. 2010;37:1084–1087.
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Cerroni L, Massone C, et al. Different histologic patterns of cutaneous granulomas in systemic lymphoma. J Am Acad Dermatol. 2004;51:600–605.
   PubMed Web of Science ®Google Scholar
• Krajnc I, Vizjak A, Hvala A, et al. Significance of histopathologic analysis of skin lesions in scleromyxedema. Light microscopy, electron microscopy, immunohistochemistry and immunofluorescence microscopy. Acta Med Austriaca. 1998;25:109–112.
   PubMedGoogle Scholar
• Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum. 2008;38:188–194.
   PubMed Web of Science ®Google Scholar
• Migkou M, Gkotzamanidou M, Terpos E, et al. Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leuk Res. 2011;35:e209–11.
   PubMed Web of Science ®Google Scholar
• Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science (80-). 1978;199:545–547.
   PubMed Web of Science ®Google Scholar
• Chockalingam R, Duvic M. Scleromyxedema: long-term follow-up after high-dose melphalan with autologous stem cell transplantation. Int J Dermatol. 2016;55:e53–3.
   PubMed Web of Science ®Google Scholar
• Açikgöz G, Özmen I, Hüseynov S, et al. A case of atypical scleromyxedema without gammopathy treated with cyclosporine. Indian J Dermatol Venereol Leprol. 2014;80:278.
   PubMed Web of Science ®Google Scholar
• Xu XL, Wu Q, Zeng XS, et al. Combination of betamethasone and methotrexate for the treatment of scleromyxoedema without paraproteinaemia. Eur J Dermatol. 2016;26:391–393.
   PubMed Web of Science ®Google Scholar
• Illa I, De la Torre C, Rojas-Garcia R, et al. Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study. Blood. 2006;108:773–774.
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Cattarini G, Sottofattori E, et al. Granulomatous reaction after intradermal injections of hyaluronic acid gel. Arch Dermatol. 2003;139:815–816.
   PubMedGoogle Scholar
• Alijotas-Reig J, Garcia-Gimenez V, Llurba E, et al. Autoimmune/inflammatory syndrome (ASIA) induced by biomaterials injection other than silicone medical grade. Lupus. 2012;21:1326–1334.
   PubMed Web of Science ®Google Scholar
• Smith JA, Kalimullah FA, Erickson CP, et al. Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy. Dermatol Online J. 2015;21:9.
   Google Scholar
• Blank M, Levy Y, Amital H, et al. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum. 2002;46:1689–1690.
   PubMed Web of Science ®Google Scholar
• Molina V, Blank M, Shoenfeld Y. Intravenous immunoglobulin and fibrosis. Clin Rev Allergy Immunol. 2005;29:321–332.
   PubMed Web of Science ®Google Scholar
• Ihn H, Yamane K, Kubo M, et al. Blockade of endogenous transforming growth factor b signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor b receptors. Arthritis Rheum. 2001;44:474–480.
   PubMed Web of Science ®Google Scholar
• Enk A. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol. 2009;19:90–98.
   PubMed Web of Science ®Google Scholar
• Ataergin S, Arpaci F, Demiriz M, et al. Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema. Am J Clin Dermatol. 2008;9:271–273.
   PubMed Web of Science ®Google Scholar
• Rey JB, Luria RB. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol. 2009;60:1037–1041.
   PubMed Web of Science ®Google Scholar
• Manríquez J, Berroeta-Mauriziano D, Andino-Navarrete R, et al. Scleromyxedema with neurological symptoms: successful treatment with immunoglobulins. Med Clin (Barc). 2015;144:47–48.
   PubMed Web of Science ®Google Scholar
• Arginelli F, Rongioletti F, Girolomoni G, et al. Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: case report. J Int Med Res. 2016 Sep;44(1suppl):109–112.
   PubMedGoogle Scholar
• Bidier M, Zschoche C, Gholam P, et al. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol. 2012;92:408–409.
   PubMed Web of Science ®Google Scholar
• Devos T, Thiessen S, Cuyle PJ, et al. Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years. Ann Hematol. 2014;93:1927–1928.
   PubMed Web of Science ®Google Scholar
• Binitha MP, Nandakumar G, Thomas D. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol. 2008;74:248–250.
   PubMed Web of Science ®Google Scholar
• Rayson D, Lust JA, Duncan A, et al. Scleromyxedema: a complete response to prednisone. Mayo Clin Proc. 1999;74:481–484.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25:451–468.
   PubMed Web of Science ®Google Scholar
• Silvestri M, Sabatini F, Scarso L, et al. Fluticasone propionate downregulates nasal fibroblast functions involved in airway inflammation and remodeling. Int Arch Allergy Immunol. 2002;128:51–58.
   PubMed Web of Science ®Google Scholar
• Lin Y-C, Wang H-C, Shen J-L. Scleromyxedema: an experience using treatment with systemic corticosteroid and review of the published work. J Dermatol. 2006;33:207–210.
   PubMed Web of Science ®Google Scholar
• Horn KB, Horn MA, Swan J, et al. A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol. 2004;51:S120–3.
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Hazini A, Rebora A. Coma associated with scleromyxedema and interferon alfa therapy. Full recovery after steroids and cyclophosphamide combined with plasmapheresis. Br J Dermatol. 2001;144:1283–1284.
   PubMed Web of Science ®Google Scholar
• Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol. 2004;140:277–280.
   PubMedGoogle Scholar
• Davies F, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma . Blood. 2001;98:210–216.
   PubMed Web of Science ®Google Scholar
• Shannon E, Noveck R, Sandoval F, et al. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. Transl Res. 2007;150:275–280.
   PubMed Web of Science ®Google Scholar
• Tsirigotis P, Venetis E, Rontogianni D, et al. Thalidomide in the treatment of myelodysplastic syndrome with fibrosis. Leuk Res. 2002;26:965–966.
   PubMed Web of Science ®Google Scholar
• Barnhill RL, Doll NJ, Millikan LE, et al. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol. 1984;11:814–819.
   PubMed Web of Science ®Google Scholar
• Sansbury JC, Cocuroccia B, Jorizzo JL, et al. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol. 2004;51:126–131.
   PubMed Web of Science ®Google Scholar
• Saniee S, Davarnia G. Scleromyxedema without paraproteinemia: treatment with thalidomide and prednisolone. Case Rep Dermatol. 2016;8:327–332.
   PubMed Web of Science ®Google Scholar
• Martins A, Paiva Lopes MJ, Tavares Belo R, et al. Scleromyxedema–thalidomide therapy. J Eur Acad Dermatol Venereol. 2008;22:622–624.
   PubMed Web of Science ®Google Scholar
• Dolenc-Voljč M, Jurčić V, Hočevar A, et al. Scleromyxedema with subcutaneous nodules: successful treatment with thalidomide and intravenous immunoglobulin. Case Rep Dermatol. 2013;5:309–315.
   PubMedGoogle Scholar
• Guarenti I, Sebastiani V, Pinto G, et al. Successful treatment of scleromyxedema with oral thalidomide. Int J Dermatol. 2013;52:631–632.
   PubMed Web of Science ®Google Scholar
• Pascualini MF, Caballero Escuti G, Valente E, et al. Response to thalidomide in scleromyxedema. Medicina (B Aires). 2013;73:252–254.
   PubMed Web of Science ®Google Scholar
• Bos R, de Waal EG, Kuiper H, et al. Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. Rheumatology (Oxford). 2011;50:1925–1926.
   PubMed Web of Science ®Google Scholar
• Tseng S, Pak G, Washenik KP, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996;35:969–979.
   PubMed Web of Science ®Google Scholar
• Goz M, Eren MN, Cakir O. Arterial thrombosis and thalidomide. J Thromb Thrombolysis. 2008;25:224–226.
   PubMed Web of Science ®Google Scholar
• Brunet-Possenti F, Hermine O, Marinho E, et al. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema. J Am Acad Dermatol. 2013;69:319–320.
   PubMed Web of Science ®Google Scholar
• Rambhia S, Rambhia K, Gulati A, et al. A case of scleromyxedema responding to lenalidomide and dexamethasone. Indian Dermatol Online J. 2017;8(1):50–53.
   PubMedGoogle Scholar
• Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol. 2001;137:1071–1072.
   PubMedGoogle Scholar
• Lacy MQ, Hogan WJ, Gertz MA, et al. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol. 2005;141:1277–1282.
   PubMedGoogle Scholar
• Iranzo P, López-Lerma I, Bladé J, et al. Scleromyxoedema treated with autologous stem cell transplantation. J Eur Acad Dermatol Venereol. 2007;21:129–130.
   PubMed Web of Science ®Google Scholar
• Shams SR, Goldstein DA, Kaufman JL, et al. Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema. Clin Lymphoma Myeloma Leuk. 2014;14:e213–5.
   PubMedGoogle Scholar
• Cañueto J, Labrador J, Román C, et al. The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. Eur J Haematol. 2012;88:450.
   PubMed Web of Science ®Google Scholar
• Fett NM, Toporcer MB, Dalmau J, et al. Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol. 2011;86:893–896.
   PubMed Web of Science ®Google Scholar
• Yeung C-K, Loong F, Kwong Y-L. Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. Br J Haematol. 2012;157:411.
   PubMed Web of Science ®Google Scholar
• Hadida E, Sayag J. Arndt-Gottron scleromyxedema; treatment with melphalan. Arch Belg Dermatol Syphigr. 1969;25:299–304.
   PubMedGoogle Scholar
• Feldman P, Shapiro I, Pick AI, et al. Scleromyxedema a dramatic response to melphalan. Arch Dermatol. 1969;99:51–56.
   PubMedGoogle Scholar
• Cao XX, Wang T, Liu YH, et al. Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy. Leuk Lymphoma. 2016;57:2934–2936.
   PubMed Web of Science ®Google Scholar
• Kuldeep CM, Mittal AK, Gupta LK, et al. Successful treatment of scleromyxedema with dexamethasone cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol. 2005;71:44–45.
   PubMedGoogle Scholar
• Aberer W, Wolff K. Scleromyxedema: immunosuppressive therapy with cyclophosphamide. Hautarzt. 1988;39:277–280.
   PubMed Web of Science ®Google Scholar
• Schirren CG, Betke M, Eckert F, et al. [Arndt-Gottron scleromyxedema. Case report and review of therapeutic possibilities]. Hautarzt. 1992;43:152–157.
   PubMedGoogle Scholar
• Wieder JM, Barton KL, Baron JM, et al. Lichen myxedematosus treated with chlorambucil. J Dermatol Surg Oncol. 1993;19:475–476.
   PubMedGoogle Scholar
• Helfrich DJ, Walker ER, Martinez AJ, et al. Scleromyxedema myopathy: case report and review of the literature. Arthritis Rheum. 1988;31:1437–1441.
   PubMedGoogle Scholar
• Mehta V, Balachandran C, Rao R. Arndt Gottron scleromyxedema: successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol. 2009;54:193–195.
   PubMedGoogle Scholar
• Milam CP, Cohen LE, Fenske NA, et al. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol. 1988;19:469–477.
   PubMed Web of Science ®Google Scholar
• Hisler BM, Savoy LB, Hashimoto K. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol. 1991;24:854–857.
   PubMed Web of Science ®Google Scholar
• Brenner S, Yust I. Treatment of scleromyxedema with etretinate. J Am Acad Dermatol. 1984;10:295–296.
   PubMed Web of Science ®Google Scholar
• Lominska-Lasota K, Rosen-Uzelac G, Reichl W, et al. Scleromyxedema therapy with isotretinoin. Z Hautkr. 1988;63:137–138.
   PubMedGoogle Scholar
• Saigoh S, Tashiro A, Fujita S, et al. Successful treatment of intractable scleromyxedema with cyclosporin A. Dermatology (Basel). 2003;207:410–411.
   PubMed Web of Science ®Google Scholar
• Krajnc I. [Arndt-Gottron scleromyxedema. Summary of 2 years treatment]. Wien Klin Wochenschr. 1997 Dec 23;109:960–963.
   PubMedGoogle Scholar
• Terheyden P, Becker JC, Lurz C, et al. Treatment of scleromyxoedema with hydroxychloroquine. J Dtsch Dermatol Ges. 2003;1:30–35.
   PubMedGoogle Scholar
• Berger JR, Dobbs MR, Terhune MH, et al. The neurologic complications of scleromyxedema. Medicine (Baltimore). 2001;80:313–319.
   PubMed Web of Science ®Google Scholar
• Tschen JA, Chang JR. Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol. 1999;40:303–307.
   PubMed Web of Science ®Google Scholar
• Ozdag F, Akar A, Eroglu E, et al. Acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa. J Dermatolog Treat. 2001;12:167–169.
   PubMed Web of Science ®Google Scholar
• Kumar N, Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler. 2004;10:85–86.
   PubMedGoogle Scholar
• Keong CH, Asaka Y, Fukuro S, et al. Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol. 1990;22:842–844.
   PubMed Web of Science ®Google Scholar
• Cokonis Georgakis CD, Falasca G, Georgakis A, et al. Scleromyxedema. Clin Dermatol. 2006;24:493–497.
   PubMedGoogle Scholar
• do Prado AD, Schmoeller D, Bisi MC, et al. Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis? Int J Dermatol. 2012;51:1013–1015.
   PubMed Web of Science ®Google Scholar
• Nieves DS, Bondi EE, Wallmark J, et al. Scleromyxedema: successful treatment of cutaneous and neurologic symptoms. Cutis. 2000;65:89–92.
   PubMed Web of Science ®Google Scholar
• Westheim AI, Lookingbill DP. Plasmapheresis in a patient with scleromyxedema. Arch Dermatol. 1987;123:786–789.
   PubMedGoogle Scholar
• D’Incan M, Franck F, Kanold J, et al. [Cutaneo-systemic papulosclerotic mucinosis (scleromyxedema): remission after extracorporeal photochemotherapy and corticoid bolus]. Ann Dermatol Venereol. 2001;128:38–41.
   PubMedGoogle Scholar
• Durani BK, Bock M, Näher H. Extracorporeal photopheresis–treatment option in scleromyxedema? Hautarzt. 2001;52:938–941.
   PubMed Web of Science ®Google Scholar
• Krasagakis K, Zouboulis CC, Owsianowski M, et al. Remission of scleromyxoedema following treatment with extracorporeal photopheresis. Br J Dermatol. 1996;135:463–466.
   PubMed Web of Science ®Google Scholar
• Adachi Y, Iba S, Horio T. Successful treatment of lichen myxoedematosus with PUVA photochemotherapy. Photodermatol Photoimmunol Photomed. 2000;16:229–231.
   PubMed Web of Science ®Google Scholar
• Farr PM, Ive FA. PUVA treatment of scleromyxoedema. Br J Dermatol. 1984;110:347–350.
   PubMed Web of Science ®Google Scholar
• Penmetcha M, Highet AS, Hopkinson JM. Failure of PUVA in lichen myxoedematosus: acceleration of associated multiple keratoacanthomas with development of squamous carcinoma. Clin Exp Dermatol. 1987;12:220–223.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Fujisawa T, Yanatori A, et al. A case of lichen myxedematosus with clearly exacerbated skin eruptions after UVB irradiation. J Dermatol. 1995;22:590–593.
   PubMedGoogle Scholar
• Cohen AM, Hodak E, David M, et al. Beneficial effect of granulocyte-colony stimulating factor in scleromyxoedema associated with severe idiopathic neutropenia. Br J Dermatol. 1996;135:626–629.
   PubMed Web of Science ®Google Scholar
• Rampino M, Garibaldi E, Ragona R, et al. Scleromyxedema: treatment of widespread cutaneous involvement by total skin electron-beam therapy. Int J Dermatol. 2007;46:864–867.
   PubMed Web of Science ®Google Scholar
• Lowe NJ, Dufton PA, Hunter RD, et al. Electron-beam treatment of scleromyxoedema. Br J Dermatol. 1982;106:449–453.
   PubMed Web of Science ®Google Scholar
• Koeppel MC, Aquilina C, Terrier G, et al. Electron-beam therapy in Arndt-Gottron’s scleromyxoedema. Br J Dermatol. 1993;129:733–735.
   PubMed Web of Science ®Google Scholar
• Leung SW, Hsu HC, Huang PH. Total skin electron beam irradiation in scleromyxoedema. Br J Radiol. 1998;71:84–86.
   PubMed Web of Science ®Google Scholar
• Bonnetblanc JM, Bedane C. Regression of scleromyxedema with topical betamethasone and dimethyl sulfoxide: a 30-month follow-up. Arch Dermatol. 1991;127:1733–1734.
   PubMedGoogle Scholar
• Rongioletti F, Zaccaria E, Cozzani E, et al. Treatment of localized lichen myxedematosus of discrete type with tacrolimus ointment. J Am Acad Dermatol. 2008;58:530–532.
   PubMed Web of Science ®Google Scholar
• Kaufman D, Truhan AP, Roenigk HH Jr. Scleromyxedema: systemic manifestations and cosmetic improvement from dermabrasion. Cutis. 1987;39:321–324.
   PubMed Web of Science ®Google Scholar
• Acikel C, Karagoz H, Kucukodaci Z. Surgical treatment of facial disfigurement due to lichen myxedematosus. Dermatol Surg. 2009;35:875–877.
   PubMed Web of Science ®Google Scholar
• Kaymen AH, Nasr A, Grekin RC. The use of carbon dioxide laser in lichen myxedematosus. J Dermatol Surg Oncol. 1989;15:862–865.
   PubMedGoogle Scholar